Prof. Dr. Beat Thürlimann
Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes
von Moos R, Caspar C, Steiner R, Angst R, Inauen R, Schmieding K, Thürlimann B. Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes. Onkologie 2010; 33:447-50.
06.07.2010Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes
06.07.2010Onkologie 2010; 33:447-50
von Moos Roger, Caspar Clemens B, Steiner Rolf, Angst Rahel, Inauen Roman, Schmieding Kerstin, Thürlimann Beat
Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
Jörger M, Thürlimann B, Huober J. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. Ann Oncol 2010; 22:17-23.
20.06.2010Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
20.06.2010Ann Oncol 2010; 22:17-23
Jörger Markus, Thürlimann Beat, Huober Jens
Brustzentrum Kantonsspital St. Gallen – von der Multidisziplinarität zur patientinnenzentrierten interdisziplinären Betriebsorganisation
Baumann M, Thürlimann B, Ruhstaller T. Brustzentrum Kantonsspital St. Gallen – von der Multidisziplinarität zur patientinnenzentrierten interdisziplinären Betriebsorganisation. Breast Care 2010; 5:188-191.
08.06.2010Brustzentrum Kantonsspital St. Gallen – von der Multidisziplinarität zur patientinnenzentrierten interdisziplinären Betriebsorganisation
08.06.2010Breast Care 2010; 5:188-191
Baumann Michael, Thürlimann Beat, Ruhstaller Thomas
Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
Hawle H, Hess D, Mueller A, Thürlimann B. Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer. Case Rep Oncol 2010; 3:131-136.
29.04.2010Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
29.04.2010Case Rep Oncol 2010; 3:131-136
Hawle H, Hess Dagmar, Mueller A, Thürlimann Beat
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
Phillips K, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Stephens A, Sun Z, Ribi K, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 2010; 19:388-95.
10.04.2010Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
10.04.2010Breast 2010; 19:388-95
Phillips Kelly-Anne, Gelber Richard D, Price Karen N, Goldhirsch Aron, Coates Alan S, Pagani Olivia, Cardoso Fatima, Thürlimann Beat, Harvey Vernon, Thompson Alastair, Stephens Alisa, Sun Zhuoxin, Ribi Karin, Bernhard Jürg
Bisphosphonates in adjuvant treatment of early breast cancer
The Scientific Board, Harbeck N, von Minckwitz G, Thürlimann B. Bisphosphonates in adjuvant treatment of early breast cancer. Crit Rev Oncol Hematol 2010; 74S1:S1.
01.04.2010Bisphosphonates in adjuvant treatment of early breast cancer
01.04.2010Crit Rev Oncol Hematol 2010; 74S1:S1
The Scientific Board, Harbeck Nadia, von Minckwitz Gunter, Thürlimann Beat
Bone targeted therapy in breast cancer: present and future
Huober J, Thürlimann B. Bone targeted therapy in breast cancer: present and future. Crit Rev Oncol Hematol 2010; 74S1:S7-S10.
01.04.2010Bone targeted therapy in breast cancer: present and future
01.04.2010Crit Rev Oncol Hematol 2010; 74S1:S7-S10
Huober Jens, Thürlimann Beat
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
Paridaens R, Coates A, Crivellari D, Holmberg S, Price K, Thürlimann B, Gelber R, Cole B, Gelber S, Goldhirsch A. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2010; 123:303-10.
27.02.2010Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
27.02.2010Breast Cancer Res Treat 2010; 123:303-10
Paridaens Robert J, Coates Alan S, Crivellari Diana, Holmberg Stig B, Price Karen N, Thürlimann Beat, Gelber Richard D, Cole Bernard F, Gelber Shari, Goldhirsch Aron
Geographic variation in breast cancer care in Switzerland
Ess S, Savidan A, Frick H, Rageth C, Vlastos G, Lütolf U, Thürlimann B. Geographic variation in breast cancer care in Switzerland. Cancer Epidemiol 2010; 34:116-21.
24.02.2010Geographic variation in breast cancer care in Switzerland
24.02.2010Cancer Epidemiol 2010; 34:116-21
Ess S, Savidan A, Frick H, Rageth Ch, Vlastos G, Lütolf U, Thürlimann Beat
Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
Antonov J, Aebi S, Altermatt H, Viale G, Giobbie-Hurder A, Thürlimann B, Oberli A, Baltzer A, Wirapati P, Delorenzi M, Popovici V, Jaggi R. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC cancer 2010; 10:37.
09.02.2010Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
09.02.2010BMC cancer 2010; 10:37
Antonov Janine, Aebi Stefan, Altermatt Hans Jorg, Viale Giuseppe, Giobbie-Hurder Anita, Thürlimann Beat, Oberli Andrea, Baltzer Anna, Wirapati Pratyaksha, Delorenzi Mauro, Popovici Vlad, Jaggi Rolf
Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer
Huober J, Schoch O, Templeton A, Spirig C, Thürlimann B. Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer. Chemotherapy 2010; 56:69-70.
08.02.2010Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer
08.02.2010Chemotherapy 2010; 56:69-70
Huober Jens, Schoch Otto, Templeton Arnoud, Spirig Christian, Thürlimann Beat
The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast Cancer
Huober J, Thürlimann B. The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast Cancer. Breast Care (Basel) 2009; 4:367-372.
16.12.2009The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast Cancer
16.12.2009Breast Care (Basel) 2009; 4:367-372
Huober Jens, Thürlimann Beat
Adjuvant! When the new world meets the old world
Huober J, Thürlimann B. Adjuvant! When the new world meets the old world. The Lancet 2009; 10:1028-9.
01.11.2009Adjuvant! When the new world meets the old world
01.11.2009The Lancet 2009; 10:1028-9
Huober Jens, Thürlimann Beat
Update of the BIG 1-98 Trial: where do we stand?
Jörger M, Thürlimann B. Update of the BIG 1-98 Trial: where do we stand?. Breast 2009; 18 Suppl 3:S78-82.
01.10.2009Update of the BIG 1-98 Trial: where do we stand?
01.10.2009Breast 2009; 18 Suppl 3:S78-82
Jörger Markus, Thürlimann Beat
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Rabaglio M, Coates A, Goldhirsch A, Gelber R, Smith I, Láng I, Nogaret J, Pienkowski T, Colleoni M, Paridaens R, Forbes J, Campone M, Mouridsen H, Thürlimann B, Hawle H, Castiglione-Gertsch M, Price K, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20:1489-98.
01.09.2009Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
01.09.2009Ann Oncol 2009; 20:1489-98
Rabaglio M, Coates A S, Goldhirsch A, Gelber R D, Smith I, Láng I, Nogaret J-M, Pienkowski T, Colleoni M, Paridaens R J, Forbes J F, Campone M, Mouridsen H, Thürlimann Beat, Hawle H, Castiglione-Gertsch M, Price K N, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
Pagani O, Goldhirsch A, Coates A, Fey M, Collins J, Thürlimann B, Lindtner J, Holmberg S, Castiglione-Gertsch M, Gelber R, Price K, International Breast Cancer Study Group (IBCSG). Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res Treat 2009; 117:319-24.
01.09.2009Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
01.09.2009Breast Cancer Res Treat 2009; 117:319-24
Pagani Olivia, Goldhirsch Aron, Coates Alan S, Fey Martin F, Collins John, Thürlimann Beat, Lindtner Jurij, Holmberg Stig B, Castiglione-Gertsch Monica, Gelber Richard D, Price Karen N, International Breast Cancer Study Group (IBCSG)
Some comments to the Pattern of Care Study
Thürlimann B. Some comments to the Pattern of Care Study. Schweiz. Krebsbulletin 2009; 3:212-212.
01.09.2009Some comments to the Pattern of Care Study
01.09.2009Schweiz. Krebsbulletin 2009; 3:212-212
Thürlimann Beat
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
BIG 1-98 Collaborative Group, Gelber R, Regan M, Price K, Forbes J, Mauriac L, Smith I, Paridaens R, Thürlimann B, Goldhirsch A, Giobbie-Hurder A, Mouridsen H, Coates A. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. NEJM 2009; 361:766-76.
20.08.2009Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
20.08.2009NEJM 2009; 361:766-76
BIG 1-98 Collaborative Group, Gelber Richard D, Regan Meredith M, Price Karen N, Forbes John F, Mauriac Louis, Smith Ian, Paridaens Robert, Thürlimann Beat, Goldhirsch Aron, Giobbie-Hurder Anita, Mouridsen Henning, Coates Alan S
ASCO 2009: What's New in Breast Cancer Therapy?
Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO 2009: What's New in Breast Cancer Therapy?. Breast Care (Basel) 2009; 4:268-271.
14.08.2009ASCO 2009: What's New in Breast Cancer Therapy?
14.08.2009Breast Care (Basel) 2009; 4:268-271
Biganzoli Laura, Bonnefoi Hervé, Cardoso Fatima, Coleman Robert, Thürlimann Beat
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
Goldhirsch A, Ingle J, Gelber R, Coates A, Thürlimann B, Senn H, Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20:1319-29.
01.08.2009Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
01.08.2009Ann Oncol 2009; 20:1319-29
Goldhirsch A, Ingle J N, Gelber R D, Coates A S, Thürlimann Beat, Senn H-J, Panel members